Daniel Schneiderman Net Worth

Daniel Schneiderman biography

Daniel H. Schneiderman serves as Chief Financial Officer of the Company. Mr. Schneiderman served as Chief Financial Officer of Biophytis SA, (ENXTPA: ALBPS) and its U.S. subsidiary, Biophytis, Inc., a European-based, clinical-stage biotechnology company focused on the development of drug candidates for age-related diseases, with a primary focus on neuromuscular diseases. From February 2012 through August 2018, Mr. Schneiderman served as Vice President of Finance, Controller and Secretary of MetaStat, Inc. (OTCQB: MTST), a publicly traded biotechnology company with a focus on Rx/Dx precision medicine solutions to treat patients with aggressive (metastatic) cancer. From 2008 through February 2012, Mr. Schneiderman was Vice President of Investment Banking at Burnham Hill Partners LLC, a boutique investment bank providing capital raising, advisory and merchant banking services. From 2004 through 2008, Mr. Schneiderman served in various roles and increasing responsibilities, including as Vice President of Investment Banking at Burnham Hill Partners, a division of Pali Capital, Inc. Previously, Mr. Schneiderman worked at H.C. Wainwright & Co., Inc. in 2004 as an investment banking analyst. Mr. Schneiderman holds a bachelor’s degree in economics from Tulane University.

How old is Daniel Schneiderman?

Daniel Schneiderman is 42, he's been the Chief Financial Officer of AzurRx BioPharma Inc since 2020. There are 8 older and no younger executives at AzurRx BioPharma Inc. The oldest executive at AzurRx BioPharma Inc is Vern Schramm, 78, who is the Independent Director.

What's Daniel Schneiderman's mailing address?

Daniel's mailing address filed with the SEC is C/O AZURRX BIOPHARMA, INC., 777 YAMATO ROAD, SUITE 502, BOCA RATON, FL, 33431.

Insiders trading at AzurRx BioPharma Inc

Over the last 8 years, insiders at AzurRx BioPharma Inc have traded over $510,400 worth of AzurRx BioPharma Inc stock and bought 335,700 units worth $727,436 . The most active insiders traders include Charles J Casamento, Edmund Burke Jr. Ross et Partners Llcbalk Matthew Pe.... On average, AzurRx BioPharma Inc executives and independent directors trade stock every 82 days with the average trade being worth of $262,052. The most recent stock trade was executed by Johan M. Spoor on 28 December 2018, trading 38,583 units of AZRX stock currently worth $50,158.

What does AzurRx BioPharma Inc do?

AzurRx BioPharma Inc executives and stock owners

AzurRx BioPharma Inc executives and other stock owners filed with the SEC include:

• James R. Sapirstein R.Ph., M.B.A.,
  CEO, Pres & Non-Independent Director
• James Pennington,
  Chief Medical Officer
• James Sapirstein,
  President, Chief Executive Officer, Director
• Alastair Riddell,
  Independent Director
• Edward Borkowski,
  Independent Chairman of the Board
• Vern Schramm,
  Independent Director
• Charles Casamento,
  Independent Director
• Gregory Oakes,
  Independent Director
• Daniel Schneiderman,
  Chief Financial Officer
• Martin Krusin M.B.A.,
  Sr. VP of Corp. Devel.
• Johan M. Spoor,
  
• Partners Llcbalk Matthew Pe...,
  
• Edmund Burke Jr. Ross,
  
• Maged Shenouda,
  CHIEF FINANCIAL OFFICER
• Daniel Dupret,
  CHIEF SCIENTIFIC OFFICER
• Mary Theresa Coelho,